Jos M Carrascosa

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/9223928/jose-m-carrascosa-publications-by-year.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

3,948 233 32 51 h-index g-index citations papers 4,651 2.2 270 5.32 L-index ext. citations avg, IF ext. papers

#	Paper	IF	Citations
233	Practical update of the Recommendations Published by the Psoriasis Group of the Spanish Academy of Dermatology and Venereology (GPS) on the Treatment of Psoriasis with Biologic Therapy. Part 1. Concepts and General Management of Psoriasis with Biologic Therapy Actas	0.5	2
232	Development of morphea during Nivolumab treatment Australasian Journal of Dermatology, 2022,	1.3	
231	[Translated article] Moderate to Severe Psoriasis in Pediatric and Young Patients: The BIOBADADERM Registry Experience <i>Actas Dermo-sifiliogr ficas</i> , 2022 ,	0.5	О
230	Survival of Guselkumab Therapy in Moderate to Severe Plaque Psoriasis at 52 Weeks in a Real-World Clinical Setting: Observational, Retrospective, Multi-Centre Study by the Spanish Psoriasis Group <i>Journal of Dermatological Treatment</i> , 2022 , 1-10	2.8	О
229	Aging in Male Wistar Rats Associates With Changes in Intestinal Microbiota, Gut Structure, and Cholecystokinin-Mediated Gut-Brain Axis Function. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2021 , 76, 1915-1921	6.4	2
228	Cost per PASI-75 responder of calcipotriol plus betamethasone dipropionate cutaneous foam versus nonbiologic systemic therapies for the treatment of plaque psoriasis in seven European countries. <i>Journal of Dermatological Treatment</i> , 2021 , 32, 701-708	2.8	6
227	Effectiveness and safety of guselkumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group. <i>Dermatologic Therapy</i> , 2021 , e15231	2.2	2
226	Therapeutic goals and treatment response evaluation in moderate to severe psoriasis: an experts opinion document. <i>Annals of Medicine</i> , 2021 , 53, 1727-1736	1.5	1
225	Increased Skin Clearance and Quality of Life Improvement with Brodalumab Compared with Ustekinumab in Psoriasis Patients with Aggravating Lifestyle Factors. <i>Dermatology and Therapy</i> , 2021 , 11, 2027-2042	4	O
224	Contributions from a multidisciplinary committee for the prevention of infections in patients with targeted immunosuppressive therapy. <i>Medicina Claica (English Edition)</i> , 2021 , 157, 489-489	0.3	
223	Prevalence and stages of chronic kidney disease in psoriasis and psoriatic arthritis: A cross-sectional study. <i>Indian Journal of Dermatology, Venereology and Leprology</i> , 2021 , 87, 321	0.8	1
222	Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study. <i>American Journal of Clinical Dermatology</i> , 2021 , 22, 567-579	7.1	25
221	Phototherapy for Prurigo Nodularis: Our Experience and a Review of the Literature. <i>Actas Dermo-sifiliogr</i> (icas, 2021 , 112, 339-344	0.5	
220	The risk of hepatic adverse events of systemic medications for psoriasis: a prospective cohort study using the BIOBADADERM registry. <i>Journal of Dermatological Treatment</i> , 2021 , 1-28	2.8	О
219	Efficacy of dimethyl fumarate treatment for moderate-to-severe plaque psoriasis: presentation extracts from the 29 EADV virtual congress, 29-31 October 2020. <i>Expert Review of Clinical Immunology</i> , 2021 , 17, 1-11	5.1	4
218	[Contributions from a multidisciplinary committee for the prevention of infections in patients with targeted immunosuppressive therapy]. <i>Medicina Claica</i> , 2021 , 157, 489-494	1	1
217	Low incidence rate of respiratory and viral infections over 5 years of treatment with tildrakizumab in patients with moderate-to-severe psoriasis: pooled analysis from reSURFACE 1 and reSURFACE 2 phase 3 trials. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021 , 35, e709-e711	4.6	1

(2020-2021)

216	Definition of minimal disease activity in psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021 , 35, 422-430	4.6	2
215	Maintenance of response following discontinuation of guselkumab and secukinumab in Spanish patients who participated in the ECLIPSE study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021 , 35, e65-e67	4.6	2
214	Time to relapse after tildrakizumab withdrawal in patients with moderate-to-severe psoriasis who were responders at week 28: post hoc analysis through 64´weeks from reSURFACE 1 trial. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021 , 35, 919-927	4.6	9
213	Factors associated with adverse COVID-19 outcomes in patients with psoriasis-insights from a global registry-based study. <i>Journal of Allergy and Clinical Immunology</i> , 2021 , 147, 60-71	11.5	77
212	Phototherapy for Prurigo Nodularis: Our Experience and a Review of the Literature. <i>Actas Dermo-sifiliogr (icas, 2021, 112, 339-344)</i>	0.5	1
211	Incidence of severe COVID-19 outcomes in psoriatic patients treated with systemic therapies during the pandemic: A Biobadaderm cohort analysis. <i>Journal of the American Academy of Dermatology</i> , 2021 , 84, 513-517	4.5	20
210	PASI 100 response rates in moderate to severe psoriasis: a systematic literature review and analysis of clinical practice guidelines. <i>Journal of Dermatological Treatment</i> , 2021 , 1-9	2.8	4
209	The Role of Photoprotection in Optimizing the Treatment of Atopic Dermatitis. <i>Dermatology and Therapy</i> , 2021 , 11, 315-325	4	1
208	Baricitinib for the treatment of atopic dermatitis. Journal of Dermatological Treatment, 2021, 1-10	2.8	3
207	Moderate to Severe Psoriasis in Pediatric and Young Patients: The BIOBADADERM Registry Experience <i>Actas Dermo-sifiliog頃icas</i> , 2021 ,	0.5	
206	Knowledge, perceptions, attitude, barriers and facilitators of biosimilars use across specialty physicians and hospital pharmacists: A national survey. <i>Farmacia Hospitalaria</i> , 2021 , 45, 240-246	0.9	
205	Brodalumab Is Associated with High Rates of Complete Clearance and Quality of Life Improvement: A Subgroup Analysis of Patients with Psoriasis and Concomitant Psoriatic Arthritis. <i>Dermatology</i> , 2021 , 1-10	4.4	O
204	Changing Trends in Drug Prescription and Causes of Treatment Discontinuation of First Biologic Over Ten Years in Psoriasis in the Spanish Biobadaderm Registry. <i>Actas Dermo-sifiliogr (icas, 2020, 111, 752-760)</i>	0.5	
203	Comorbidities in Atopic Dermatitis: An Update and Review of Controversies. <i>Actas Dermo-sifiliogrficas</i> , 2020 , 111, 481-486	0.5	3
202	Managing Psoriasis Consultations During the COVID-19 Pandemic: Recommendations From the Psoriasis Group of the Spanish Academy of Dermatology and Venereology (AEDV). <i>Actas Dermo-sifiliogr</i> icas, 2020 , 111, 802-804	0.5	2
201	Ichthyosiform eruption and facial erythema secondary to ponatinib therapy. <i>JDDG - Journal of the German Society of Dermatology</i> , 2020 , 18, 743-747	1.2	1
200	Patch Testing During the COVID-19 Pandemic: Recommendations of the AEDV's Spanish Contact Dermatitis and Skin Allergy Research Group (GEIDAC). <i>Actas Dermo-sifiliogr</i> (GEIDAC) (111, 650-654)	0.5	4
199	The role of the interleukin-23/Th17 pathway in cardiometabolic comorbidity associated with psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020 , 34, 1695-1706	4.6	29

198	Pemetrexed-induced oedema of the eyelids and scalp in a patient with metastatic lung cancer. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e322-e324	4.6	O
197	Long-term safety of nine systemic medications for psoriasis: A cohort study using the Spanish Registry of Adverse Events for Biological Therapy in Dermatological Diseases (BIOBADADERM) Registry. <i>Journal of the American Academy of Dermatology</i> , 2020 , 83, 139-150	4.5	16
196	Real-world effectiveness and safety of apremilast in psoriasis at 52 weeks: a retrospective, observational, multicentre study by the Spanish Psoriasis Group. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020 , 34, 2821-2829	4.6	14
195	The Use of Apremilast in Psoriasis: A Delphi Study. Actas Dermo-sifiliogr¶icas, 2020, 111, 115-134	0.5	6
194	Apremilast for psoriasis treatment. Giornale Italiano Di Dermatologia E Venereologia, 2020, 155, 421-433	3 0.8	2
193	Cutaneous Manifestations in the Context of SARS-CoV-2 Infection (COVID-19). <i>Actas Dermo-sifiliogr</i> (COVID-19). <i>Actas</i>	0.5	17
192	Changing Trends in Drug Prescription and Causes of Treatment Discontinuation of First Biologic Over Ten Years in Psoriasis in the Spanish Biobadaderm Registry. <i>Actas Dermo-sifiliogr dicas</i> , 2020 , 111, 752-760	0.5	3
191	Biosimilars in the Treatment of Psoriasis: An Update. <i>Actas Dermo-sifiliogr ficas</i> , 2020 , 111, 809-814	0.5	2
190	Biosimilars in the Treatment of Psoriasis: An Update. <i>Actas Dermo-sifiliogr ficas</i> , 2020 , 111, 809-814	0.5	
189	Patch Testing During the COVID-19 Pandemic: Recommendations of the AEDV's Spanish Contact Dermatitis and Skin Allergy Research Group (GEIDAC). <i>Actas Dermo-sifiliogr</i> (GEIDAC) is a contact provided by the AEDV's Spanish Contact part of the AEDV's Spanish Contac	0.5	78
188	The Use of Apremilast in Psoriasis: A Delphi Study. <i>Actas Dermo-sifiliogr (Eicas, 2020)</i> , 111, 115-134	0.5	1
187	Cutaneous Manifestations in the Context of SARS-CoV-2 Infection (COVID-19). <i>Actas Dermo-sifiliogr</i> (Jicas, 2020 , 111, 734-742	0.5	4
186	Spotlight on Topical Long-Term Management of Plaque Psoriasis. <i>Clinical, Cosmetic and Investigational Dermatology</i> , 2020 , 13, 495-498	2.9	3
185	Effectiveness and safety of ustekinumab 90 mg in patients weighing 100 kg or less: a retrospective, observational, multicenter study. <i>Journal of Dermatological Treatment</i> , 2020 , 31, 222-226	2.8	6
184	Drug survival of conventional systemic and biologic therapies for moderate-to-severe psoriasis in clinical practice in Spain: prospective results from the SAHARA study. <i>Journal of Dermatological Treatment</i> , 2020 , 31, 344-351	2.8	5
183	The risk of urinary tract infections in patients with psoriasis on systemic medications in Biobadaderm Registry: A prospective cohort study. <i>Journal of the American Academy of Dermatology</i> , 2020 , 82, 738-741	4.5	4
182	Treatment Appraisal Reports: Usefulness and Transparency. Actas Dermo-sifiliogr¶icas, 2020, 111, 3-6	0.5	2
181	Biosimilar and interchangeable: Inseparable scientific concepts?. <i>British Journal of Clinical Pharmacology</i> , 2019 , 85, 2460-2463	3.8	9

(2018-2019)

180	Women with moderate-to-severe psoriasis in Spain (BIOBADADERM registry) show more than a 50% reduction in age-adjusted fertility rate when compared with the general population. <i>British Journal of Dermatology</i> , 2019 , 181, 1085-1087	4	5	
179	Expert consensus on the persistence of biological treatments in moderate-to-severe psoriasis. Journal of the European Academy of Dermatology and Venereology, 2019 , 33, 1214-1223	4.6	5	
178	Osteoporosis and Psoriasis. <i>Actas Dermo-sifiliogr (ficas, 2019, 110, 642-652)</i>	0.5		
177	Osteoporosis and Psoriasis. <i>Actas Dermo-sifiliogr</i> Ficas, 2019 , 110, 642-652	0.5	7	
176	Actinic lichen planus triggered by drug photosensitivity. <i>Photodermatology Photoimmunology and Photomedicine</i> , 2019 , 35, 124-126	2.4	4	
175	Safety and effectiveness of conventional systemic therapy and biological drugs in patients with moderate to severe psoriasis and HIV infection: a retrospective multicenter study. <i>Journal of Dermatological Treatment</i> , 2019 , 30, 461-465	2.8	12	
174	Caloric restriction attenuates aging-induced cardiac insulin resistance in male Wistar rats through activation of PI3K/Akt pathway. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2019 , 29, 97-105	4.5	12	
173	Treatment of patients with plaque psoriasis with secukinumab in a real-life setting: a 52-week, multicenter, retrospective study in Spain. <i>Journal of Dermatological Treatment</i> , 2019 , 30, 424-429	2.8	37	
172	Usefulness and correlation with clinical response of serum ustekinumab levels measured at 6 weeks versus 12 weeks. <i>Journal of Dermatological Treatment</i> , 2019 , 30, 35-39	2.8	9	
171	Effects of etanercept on the patient-perceived results (PROs) in patients with moderate-to-severe plaque psoriasis: systematic review of the literature and meta-analysis. <i>Journal of Dermatological Treatment</i> , 2018 , 29, 806-811	2.8	5	
170	Change over time in the rates of adverse events in patients receiving systemic therapy for psoriasis: A cohort study. <i>Journal of the American Academy of Dermatology</i> , 2018 , 78, 798-800	4.5	5	
169	Biosimilar Drugs for Psoriasis: Principles, Present, and Near Future. <i>Dermatology and Therapy</i> , 2018 , 8, 173-194	4	32	
168	New therapies versus first-generation biologic drugs in psoriasis: a review of adverse events and their management. <i>Expert Review of Clinical Immunology</i> , 2018 , 14, 259-273	5.1	9	
167	Correlation between trough serum levels of adalimumab and absolute PASI score in a series of patients with psoriasis. <i>Journal of Dermatological Treatment</i> , 2018 , 29, 140-144	2.8	7	
166	Study of insulin vascular sensitivity in aortic rings and endothelial cells from aged rats subjected to caloric restriction: Role of perivascular adipose tissue. <i>Experimental Gerontology</i> , 2018 , 109, 126-136	4.5	8	
165	Position statement for the management of comorbidities in psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018 , 32, 2058-2073	4.6	33	
164	Redefining the therapeutic objective in psoriatic patients candidates for biological therapy. <i>Journal of Dermatological Treatment</i> , 2018 , 29, 334-346	2.8	25	
163	Genetic and experimental evidence for the involvement of the CD6 lymphocyte receptor in psoriasis. <i>Cellular and Molecular Immunology</i> , 2018 , 15, 898-906	15.4	11	

162	Paradoxical Reactions to Biologic Therapy in Psoriasis: A Review of the Literature. <i>Actas Dermo-sifiliogr (icas, 2018, 109, 791-800)</i>	0.5	3
161	Determining the Value of Two Biologic Drugs for Chronic Inflammatory Skin Diseases: Results of a Multi-Criteria Decision Analysis. <i>BioDrugs</i> , 2018 , 32, 281-291	7.9	8
160	Paradoxical Reactions to Biologic Therapy in Psoriasis: A Review of the Literature. <i>Actas Dermo-sifiliogr</i> (2018, 109, 791-800)	0.5	21
159	Possible paradoxical occurrence of inflammatory arthritis in patients with psoriasis treated with biologics: findings in the Biobadaderm cohort. <i>British Journal of Dermatology</i> , 2017 , 176, 797-799	4	8
158	Management of Biologic Therapy in Moderate to Severe Psoriasis in Surgical Patients: Data From the Spanish Biobadaderm Registry. <i>Actas Dermo-sifiliogr</i> (2017), 108, 52-58	0.5	
157	Comparison of phenotype, comorbidities, therapy and adverse events between psoriatic patients with and without psoriatic arthritis. Biobadaderm registry. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017 , 31, 1021-1028	4.6	7
156	Increase in minimal erythemal dose following oral administration of an antioxidant complex based on a mix of carotenoids: Double-blind, placebo-controlled trial. <i>Photodermatology Photoimmunology and Photomedicine</i> , 2017 , 33, 284-286	2.4	4
155	Adverse events associated with discontinuation of the biologics/classic systemic treatments for moderate-to-severe plaque psoriasis: data from the Spanish Biologics Registry, Biobadaderm. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017 , 31, 1700-1708	4.6	14
154	Fixed sunlight eruption: a new idiopathic photodermatosis rather than a variant of fixed drug eruption. <i>Photodermatology Photoimmunology and Photomedicine</i> , 2017 , 33, 222-224	2.4	1
153	Psoriasis and Nonalcoholic Fatty Liver Disease. <i>Actas Dermo-sifiliogr</i> icas, 2017 , 108, 506-514	0.5	23
152	Clinical, Diagnostic, and Therapeutic Implications in Psoriasis Associated With Cardiovascular Disease. <i>Actas Dermo-sifiliogr (icas, 2017, 108, 800-808)</i>	0.5	
151	Immune-mediated inflammatory diseases differently affect IGRAs' accuracy for latent tuberculosis infection diagnosis in clinical practice. <i>PLoS ONE</i> , 2017 , 12, e0189202	3.7	11
150	New treatments in psoriasis. <i>Medicina Clūica (English Edition)</i> , 2017 , 149, 157-159	0.3	
149	Clinical, Diagnostic, and Therapeutic Implications in Psoriasis Associated With Cardiovascular Disease. <i>Actas Dermo-sifiliogrficas</i> , 2017 , 108, 800-808	0.5	7
148	Psoriasis and Psychiatric Disorders: The Next Frontier. <i>Actas Dermo-sifiliogr (icas, 2017)</i> , 108, 502-505	0.5	4
147	Reliability of the MDi Psoriasis Application to Aid Therapeutic Decision-Making in Psoriasis. <i>Actas Dermo-sifiliogr</i> Jicas, 2017 , 108, 650-656	0.5	1
146	Reliability of the MDi Psoriasis Application to Aid Therapeutic Decision-Making in Psoriasis. <i>Actas Dermo-sifiliogr</i> () cas, 2017 , 108, 650-656	0.5	4
145	Optimizing Anti-Inflammatory and Immunomodulatory Effects of Corticosteroid and Vitamin D Analogue Fixed-Dose Combination Therapy. <i>Dermatology and Therapy</i> , 2017 , 7, 265-279	4	21

(2015-2017)

144	Phototoxic reaction to a combined oral contraceptive (levonorgestrel/ethinylestradiol). <i>Photochemical and Photobiological Sciences</i> , 2017 , 16, 1381-1383	4.2	6
143	Psoriasis and Psychiatric Disorders: The Next Frontier. <i>Actas Dermo-sifiliogr dicas</i> , 2017 , 108, 502-505	0.5	
142	Psoriasis and Nonalcoholic Fatty Liver Disease. <i>Actas Dermo-sifiliogr¶icas</i> , 2017 , 108, 506-514	0.5	3
141	Management of Biologic Therapy in Moderate to Severe Psoriasis in Surgical Patients: Data From the Spanish Biobadaderm Registry. <i>Actas Dermo-sifiliogr</i> (Jicas, 2017, 108, 52-58)	0.5	3
140	Treatment with ustekinumab in a Spanish cohort of patients with psoriasis and psoriatic arthritis in daily clinical practice. <i>Clinical Rheumatology</i> , 2017 , 36, 439-443	3.9	13
139	Perception of psoriasis treatment in the outpatient setting: survey of patients and their prescribing physicians. <i>Journal of Dermatological Treatment</i> , 2017 , 28, 188-199	2.8	6
138	Infections in Moderate to Severe Psoriasis Patients Treated with Biological Drugs Compared to Classic Systemic Drugs: Findings from the BIOBADADERM Registry. <i>Journal of Investigative Dermatology</i> , 2017 , 137, 313-321	4.3	64
137	Photoinduced target-like drug reaction to naproxen. <i>Photodermatology Photoimmunology and Photomedicine</i> , 2016 , 32, 323-326	2.4	0
136	Kidney Disease and Psoriasis. A New Comorbidity?. <i>Actas Dermo-sifiliogr (icas, 2016, 107, 823-829)</i>	0.5	2
135	Methotrexate in Moderate to Severe Psoriasis: Review of the Literature and Expert Recommendations. <i>Actas Dermo-sifiliogr</i> (2016), 107, 194-206	0.5	2
134	Methotrexate in Moderate to Severe Psoriasis: Review of the Literature and Expert Recommendations. <i>Actas Dermo-sifiliogr dicas</i> , 2016 , 107, 194-206	0.5	28
133	Development of clinical prediction models for good or bad response to classic systemic drugs, anti-TNFs, and ustekinumab in psoriasis, based on the BIOBADADERM cohort. <i>Journal of Dermatological Treatment</i> , 2016 , 27, 203-9	2.8	12
132	Adhesion Molecules Associated with Female Genital Tract Infection. <i>PLoS ONE</i> , 2016 , 11, e0156605	3.7	4
131	Expert Recommendations on Treating Psoriasis in Special Circumstances (Part II). <i>Actas Dermo-sifiliogricas</i> , 2016 , 107, 712-729	0.5	5
130	Kidney Disease and Psoriasis. A New Comorbidity?. <i>Actas Dermo-sifiliogr ticas</i> , 2016 , 107, 823-829	0.5	5
129	Expert Recommendations on Treating Psoriasis in Special Circumstances (Part II). <i>Actas Dermo-sifiliogr</i> (icas, 2016 , 107, 712-729	0.5	
128	Toll-like receptor 9 promoter polymorphism as a predictive factor of narrow-band UVB phototherapy response in patients with psoriasis. <i>Photodermatology Photoimmunology and Photomedicine</i> , 2015 , 31, 98-103	2.4	7
127	Hidradenitis Suppurativa: New Opportunities for an Orphan Skin Disease. <i>Actas Dermo-sifiliogr</i> [icas, 2015 , 106, 448-51	0.5	4

126	Use of off-label doses is frequent in biologic therapy for moderate to severe psoriasis: A cross-sectional study in clinical practice. <i>Journal of Dermatological Treatment</i> , 2015 , 26, 502-6	2.8	22
125	Safety of classic and biologic systemic therapies for the treatment of psoriasis in elderly: an observational study from national BIOBADADERM registry. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015 , 29, 858-64	4.6	32
124	Hidradenitis Suppurativa: New Opportunities for an Orphan Skin Disease. <i>Actas Dermo-sifiliogr</i> J <i>icas</i> , 2015 , 106, 448-451	0.5	
123	Does the treatment ladder for systemic therapy in moderate to severe psoriasis only go up? The percentage of patients with severe psoriasis on biologics increases over time. <i>Actas Dermo-sifiliogrficas</i> , 2015 , 106, 638-43	0.5	9
122	Does the treatment ladder for systemic therapy in moderate to severe psoriasis only go up? The percentage of patients with severe psoriasis on biologics increases over time. <i>Actas Dermo-sifiliogr ficas</i> , 2015 , 106, 638-643	0.5	
121	Lupus erythematosus tumidus: a clinical and histological study of 25 cases. <i>Lupus</i> , 2015 , 24, 751-5	2.6	11
120	Expert Recommendations on Treating Psoriasis in Special Circumstances. <i>Actas Dermo-sifiliogr (icas policum)</i> , 2015 , 106, 292-309	0.5	1
119	Expert recommendations on treating psoriasis in special circumstances. <i>Actas Dermo-sifiliogr</i> f <i>icas</i> , 2015 , 106, 292-309	0.5	9
118	Risk of adverse events in psoriasis patients receiving classic systemic drugs and biologics in a 5-year observational study of clinical practice: 2008-2013 results of the Biobadaderm registry. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015 , 29, 156-63	4.6	47
117	Effects of age and caloric restriction on the cardiac and coronary response to endothelin-1 in rats. <i>Experimental Gerontology</i> , 2014 , 60, 183-9	4.5	4
116	Clinical relevance of immunogenicity of biologics in psoriasis: implications for treatment strategies. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014 , 28, 1424-30	4.6	47
115	Diagnosis of tuberculosis infection by interferon-gamma release assays in patients with psoriasis. Journal of Infection, 2014 , 69, 600-6	18.9	13
114	One-year safety and efficacy of ustekinumab and results of dose adjustment after switching from inadequate methotrexate treatment: the TRANSIT randomized trial in moderate-to-severe plaque psoriasis. <i>British Journal of Dermatology</i> , 2014 , 170, 435-44	4	32
113	Transition to ustekinumab in patients with moderate-to-severe psoriasis and inadequate response to methotrexate: a randomized clinical trial (TRANSIT). <i>British Journal of Dermatology</i> , 2014 , 170, 425-	34 ⁴	18
112	Drug Survival in Biologic Therapy. Do We Know What it Means? Can We Calculate it?. <i>Actas Dermo-sifiliogr (icas, 2014, 105, 729-733)</i>	0.5	
111	Realidades y retos de la fotoproteccia en la infancia. <i>Actas Dermo-sifiliogr</i> icas, 2014 , 105, 253-262	0.5	13
110	Cumulative life course impairment: the imprint of psoriasis on the patient's life. <i>Actas Dermo-sifiliogr</i> (icas, 2014 , 105, 128-34	0.5	28
109	Obesity and psoriasis: inflammatory nature of obesity, relationship between psoriasis and obesity, and therapeutic implications. <i>Actas Dermo-sifiliogr licas</i> , 2014 , 105, 31-44	0.5	74

108	Elaboracifi mediante el mEodo Delphi de recomendaciones para el manejo coordinado (reumatEbgo/dermatEbgo) de la artritis psorifica. <i>Actas Dermo-sifiliogr</i> Ficas, 2014 , 105, 216-232	0.5	22
107	Prevalence of Psoriasis in Spain in the Age of Biologics. <i>Actas Dermo-sifiliogr</i> 師cas, 2014 , 105, 504-509	0.5	3
106	Sun protection in children: realities and challenges. Actas Dermo-sifiliogras, 2014, 105, 253-62	0.5	2
105	Drug survival in biologic therapy. Do we know what it means? Can we calculate it?. <i>Actas Dermo-sifiliogr</i> ()icas, 2014 , 105, 729-33	0.5	13
104	Body mass index in patients with moderate-to-severe psoriasis in Spain and its impact as an independent risk factor for therapy withdrawal: results of the Biobadaderm Registry. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014 , 28, 907-14	4.6	47
103	Cardiovascular risk factors and cardiovascular diseases in patients with moderate to severe psoriasis under systemic treatment. PSO-RISK, descriptive study. <i>European Journal of Dermatology</i> , 2014 , 24, 662-9	0.8	3
102	Prevalence of psoriasis in Spain in the age of biologics. <i>Actas Dermo-sifiliogr (icas, 2014, 105, 504-9)</i>	0.5	74
101	Recommendations for the coordinated management of psoriatic arthritis by rheumatologists and dermatologists: a Delphi study. <i>Actas Dermo-sifiliogr</i> (Ecas, 2014 , 105, 216-32)	0.5	9
100	Effectiveness and safety of psoralen-UVA (PUVA) topical therapy in palmoplantar psoriasis: a report on 48 patients. <i>Actas Dermo-sifiliogr (Eicas, 2013)</i> , 104, 418-25	0.5	6
99	Adherence and Patient Satisfaction With Topical Treatment in Psoriasis, and the Use, and Organoleptic Properties of Such Treatments: A Delphi Study With an Expert Panel and Members of the Psoriasis Group of the Spanish Academy of Dermatology and Venereology. <i>Actas</i>	0.5	4
98	Guidelines for the use of acitretin in psoriasis. Psoriasis Group of the Spanish Academy of Dermatology and Venereology. <i>Actas Dermo-sifiliogr</i> (2013), 104, 598-616	0.5	21
97	Circulating levels of lipocalin-2 and retinol-binding protein-4 are increased in psoriatic patients and correlated with baseline PASI. <i>Archives of Dermatological Research</i> , 2013 , 305, 105-12	3.3	50
96	Pityriasis rubra pilaris-like reaction induced by imatinib. <i>Clinical and Experimental Dermatology</i> , 2013 , 38, 520-2	1.8	12
95	Immunogenicity in biologic therapy: implications for dermatology. <i>Actas Dermo-sifiliogr</i> 何cas, 2013 , 104, 471-9	0.5	27
94	Directrices espa B las basadas en la evidencia para el tratamiento de la psoriasis con agentes biolgicos, 2013. I. Consideraciones de eficacia y seleccifi del tratamiento. <i>Actas Dermo-sifiliogr</i> icas, 2013 , 104, 694-709	0.5	83
93	Spanish evidence-based guidelines on the treatment of psoriasis with biologic agents, 2013. Part 1: on efficacy and choice of treatment. Spanish Psoriasis Group of the Spanish Academy of Dermatology and Venereology. <i>Actas Dermo-sifiliogr</i> ficas, 2013, 104, 694-709	0.5	17
92	Adherence and patient satisfaction with topical treatment in psoriasis, and the use, and organoleptic properties of such treatments: a Delphi study with an expert panel and members of the Psoriasis Group of the Spanish Academy of Dermatology and Venereology. <i>Actas</i>	0.5	31
91	Dermo-sifiliogrificas, 2013 , 104, 488-96 Eficacia y seguridad en terapia con psoralen-UVA (PUVA) tipica en psoriasis palmoplantar. Experiencia en una serie de 48 pacientes. <i>Actas Dermo-sifiliogrificas</i> , 2013 , 104, 418-425	0.5	8

90	Lipopolysaccharide-binding protein is increased in patients with psoriasis with metabolic syndrome, and correlates with C-reactive protein. <i>Clinical and Experimental Dermatology</i> , 2013 , 38, 81-4	1.8	21
89	Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicentre study in a clinical setting. British Journal of Dermatology, 2013, 168, 609-16	4	73
88	The role of FcIreceptor polymorphisms in the response to antiEumor necrosis factor therapy in psoriasis A pharmacogenetic study. <i>JAMA Dermatology</i> , 2013 , 149, 1033-9	5.1	32
87	Impairment of skeletal muscle insulin action with aging in Wistar rats: role of leptin and caloric restriction. <i>Mechanisms of Ageing and Development</i> , 2012 , 133, 306-16	5.6	9
86	Effect of narrowband ultraviolet B therapy on inflammatory markers and body fat composition in moderate to severe psoriasis. <i>British Journal of Dermatology</i> , 2012 , 166, 1237-44	4	39
85	Mecanismo de accili de ustekinumab y su relevancia en la patogliesis de la psoriasis. Impacto en el sistema inmune. <i>Actas Dermo-sifiliogr</i> licas, 2012 , 103, 7-15	0.5	
84	Risk of serious adverse events associated with biologic and nonbiologic psoriasis systemic therapy: patients ineligible vs eligible for randomized controlled trials. <i>Archives of Dermatology</i> , 2012 , 148, 463	-70	121
83	BIOBADADERM, the Spanish Registry of Adverse Events Associated With Biologic Drugs in Dermatology: First Report. <i>Actas Dermo-sifiliogr (icas, 2011)</i> , 102, 132-141	0.5	
82	Narrowband UV-B, Monochromatic Excimer Laser, and Photodynamic Therapy in Psoriasis: A Consensus Statement of the Spanish Psoriasis Group. <i>Actas Dermo-sifiliogr</i> (2011), 102, 175-186	0.5	2
81	Clinical Characteristics and Disease Course in Patients Treated With Efalizumab Following Suspension of Marketing Authorization by the European Medicines Agency: A Multicenter Observational Study. <i>Actas Dermo-sifiliogr</i> 2011, 102, 354-364	0.5	
80	Development of insulin resistance during aging: involvement of central processes and role of adipokines. <i>Current Protein and Peptide Science</i> , 2011 , 12, 305-15	2.8	22
79	A black tongue in a young woman. <i>Clinical and Experimental Dermatology</i> , 2011 , 36, 429-30	1.8	3
78	Patch testing in children with hand eczema. A 5-year multicentre study in Spain. <i>Contact Dermatitis</i> , 2011 , 65, 213-9	2.7	25
77	El futuro se hace presente en fotoproteccili solar. <i>Piel</i> , 2011 , 26, 311-314	0.1	1
76	Age-associated development of inflammation in Wistar rats: Effects of caloric restriction. <i>Archives of Physiology and Biochemistry</i> , 2011 , 117, 140-50	2.2	32
75	CCL4L polymorphisms and CCL4/CCL4L serum levels are associated with psoriasis severity. <i>Journal of Investigative Dermatology</i> , 2011 , 131, 1830-7	4.3	20
74	Commentary on European and British Guidelines for the Treatment of Psoriasis. <i>Actas Dermo-sifiliogr (icas, 2010, 101, 285-290)</i>	0.5	
73	Guidelines on the Use of Methotrexate in Psoriasis. Actas Dermo-sifiliogr∰icas, 2010 , 101, 600-613	0.5	2

72	Leukemia Cutis Arising at the Site of Injection of a Tetanus Vaccine Booster. <i>Actas Dermo-sifiliogr¶icas</i> , 2010 , 101, 727-729	0.5	
71	A new era in the management of psoriasis? The biologics: facts and controversies. <i>Clinics in Dermatology</i> , 2010 , 28, 81-7	3	23
70	Comentarios a las directrices europeas y britflicas sobre el tratamiento de la psoriasis. <i>Actas Dermo-sifiliogr</i> f icas, 2010 , 101, 285-290	0.5	6
69	Guidelines on the Use of Methotrexate in Psoriasis. <i>Actas Dermo-sifiliogr (icas, 2010)</i> , 101, 600-613	0.5	53
68	Efectos adversos observados durante la terapia biolਊica en la psoriasis. Resultados de una encuesta al Grupo Espa⊕l de Psoriasis. <i>Actas Dermo-sifiliogr∰icas</i> , 2010 , 101, 156-163	0.5	10
67	The effect of aging on insulin signalling pathway is tissue dependent: central role of adipose tissue in the insulin resistance of aging. <i>Mechanisms of Ageing and Development</i> , 2009 , 130, 189-97	5.6	25
66	Changes in the neuroendocrine control of energy homeostasis by adiposity signals during aging. <i>Experimental Gerontology</i> , 2009 , 44, 20-5	4.5	30
65	Generalized cutaneous drug eruption due to strontium ranelate. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2009 , 23, 321-2	4.6	4
64	Revisili actualizada del tratamiento tipico de la psoriasis. Actas Dermo-sifiliogrificas, 2009 , 100, 190-200	0.5	24
63	Documento de consenso sobre la evaluaci∄ y el tratamiento de la psoriasis moderada/grave del Grupo Espa⊟l de Psoriasis de la Academia Espa⊖la de Dermatolog∄ y Venereolog∄. <i>Actas</i> <i>Dermo-sifiliogr∯icas</i> , 2009 , 100, 277-286	0.5	80
62	Directrices espa B las basadas en la evidencia para el tratamiento de la psoriasis moderada a grave con agentes biolgicos. <i>Actas Dermo-sifiliogr¶icas</i> , 2009 , 100, 386-413	0.5	61
61	Perfil de los pacientes con dermatosis en las manos remitidos a la Unidad de Contacto de un hospital terciario e impacto de las pruebas epicut∏eas en el diagn∏tico. <i>Actas</i> <i>Dermo-sifiliogr∏icas</i> , 2009 , 100, 493-498	0.5	4
60	The expression of rat resistin isoforms is differentially regulated in visceral adipose tissues: effects of aging and food restriction. <i>Metabolism: Clinical and Experimental</i> , 2009 , 58, 204-11	12.7	16
59	Narrowband Ultraviolet B Therapy in Psoriasis: Reality, Outlook, and Uncertainty. <i>Actas Dermo-sifiliogr</i> [icas, 2009, 100, 3-6	0.5	
58	Update of the Topical Treatment of Psoriasis. Actas Dermo-sifiliogr¶icas, 2009, 100, 190-200	0.5	1
57	Spanish Evidence-Based Guidelines on the Treatment of Moderate to Severe Psoriasis with Biologic Agents. <i>Actas Dermo-sifiliogr</i> ficas, 2009 , 100, 386-413	0.5	1
56	Characteristics of Patients With Hand Dermatitis Referred to the Contact Dermatitis Unit of a Tertiary Hospital and Impact of Patch Testing on Diagnosis. <i>Actas Dermo-sifiliogr</i> (Ficas, 2009), 100, 493-49.	8 ^{0.5}	
55	Disseminated Strongyloides stercoralis infection with a cutaneous presentation in an immunosuppressed patient. <i>European Journal of Dermatology</i> , 2009 , 19, 404-5	0.8	2

54	Basal cell carcinoma. Cancer Treatment and Research, 2009, 146, 263-78	3.5	8
53	Successful treatment of recalcitrant palmoplantar psoriasis with efalizumab. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2008 , 22, 1131-4	4.6	10
52	Effects of chronic acarbose treatment on adipocyte insulin responsiveness, serum levels of leptin and adiponectin and hypothalamic NPY expression in obese diabetic Wistar rats. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2008 , 35, 256-61	3	8
51	Reply to: Ireatment of Minor and Benign Skin Lesions in the Spanish Public Health System: Experience in Health Area 19 of the Autonomous Community of Valencia (Actas Dermo-sifiliogras, 2008, 99, 234-235	0.5	
50	Acute dermal abscesses caused by Serratia marcescens. <i>Journal of the American Academy of Dermatology</i> , 2008 , 58, 891-3	4.5	8
49	RBlica: «Patologa cutaea benigna banal y sistema pBlico. Experiencia en el Departamento de Salud 19 de la Comunidad Valenciana». <i>Actas Dermo-sifiliogras</i> , 2008 , 99, 234-235	0.5	
48	Efectos adversos de la fototerapia: clāica y manejo. <i>Piel</i> , 2008 , 23, 447-452	0.1	4
47	Consensus Document on Therapy With Bath Psoralen-UV-A. Actas Dermo-sifiliogr¶icas, 2007, 98, 164-170	00.5	
46	Should Minor and Benign Cutaneous Lesions Be Treated by the Health Service?. <i>Actas Dermo-sifiliogr (icas, 2007)</i> , 98, 236-239	0.5	
45	Effects of narrowband UV-B on pharmacodynamic markers of response to therapy: an immunohistochemical study over sequential samples. <i>Journal of Cutaneous Pathology</i> , 2007 , 34, 769-76	1.7	21
44	Managing moderate-to-severe psoriasis with efalizumab: experience at a single Spanish institute. British Journal of Dermatology, 2007 , 156 Suppl 2, 24-9	4	12
43	Effective management of a psoriatic flare with narrowband UVB phototherapy during efalizumab therapy without discontinuing treatment. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2007 , 21, 828-9	4.6	12
42	Treatment of inverse psoriasis with excimer therapy and tacrolimus ointment. <i>Dermatologic Surgery</i> , 2007 , 33, 361-3	1.7	16
41	A tattoo reaction in a sentinel lymph node from a patient with melanoma. <i>Dermatologic Surgery</i> , 2007 , 33, 766-7	1.7	16
40	Allergic contact dermatitis to 2(thiocyano-methylthio) benzothiazole present in a packaging wood. <i>Contact Dermatitis</i> , 2007 , 57, 121-2	2.7	2
39	Impaired central insulin response in aged Wistar rats: role of adiposity. Endocrinology, 2007, 148, 5238-4	17 .8	41
38	Effect of age and moderate food restriction on insulin sensitivity in Wistar rats: role of adiposity. Journal of Endocrinology, 2007 , 194, 131-41	4.7	103
37	Effective management of a psoriatic flare with narrowband UVB phototherapy during efalizumab therapy without discontinuing treatment. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2007 , 070410044732014-???	4.6	

[1998-2006]

36	Altered subcellular distribution of IRS-1 and IRS-3 is associated with defective Akt activation and GLUT4 translocation in insulin-resistant old rat adipocytes. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2006 , 1763, 197-206	4.9	7	
35	A prospective evaluation of the cost of psoriasis in Spain (EPIDERMA project: phase II). <i>Journal of the European Academy of Dermatology and Venereology</i> , 2006 , 20, 840-5	4.6	27	
34	Narrow-band ultraviolet B in aquagenic pruritus. British Journal of Dermatology, 2005, 153, 1233-4	4	20	
33	Differential gene expression of insulin receptor isoforms A and B and insulin receptor substrates 1, 2 and 3 in rat tissues: modulation by aging and differentiation in rat adipose tissue. <i>Journal of Molecular Endocrinology</i> , 2005 , 34, 153-61	4.5	49	
32	Leptin impairs insulin signaling in rat adipocytes. <i>Diabetes</i> , 2004 , 53, 347-53	0.9	93	
31	Fototerapia y fotoquimioterapia. <i>Actas Dermo-sifiliogr</i> ficas, 2004 , 95, 259-284	0.5	10	
30	Isolation and biological characterization of a 6-kDa protein from hepatopancreas of lobster Panulirus argus with insulin-like effects. <i>General and Comparative Endocrinology</i> , 2003 , 131, 284-90	3	22	
29	Terapia UVB de banda estrecha en prurigo nodular. <i>Actas Dermo-sifiliogr</i> fficas, 2003 , 94, 294-299	0.5	5	
28	Long-term food restriction prevents ageing-associated central leptin resistance in wistar rats. <i>Diabetologia</i> , 2002 , 45, 997-1003	10.3	94	
27	Ageing increases SOCS-3 expression in rat hypothalamus: effects of food restriction. <i>Biochemical and Biophysical Research Communications</i> , 2002 , 296, 425-8	3.4	79	
26	Activation of MAP kinase by insulin and vanadate in adipocytes from young and old rats. <i>Molecular and Cellular Endocrinology</i> , 2002 , 189, 77-84	4.4	23	
25	Decreased leptin uptake in hypothalamic nuclei with ageing in Wistar rats. <i>Journal of Endocrinology</i> , 2001 , 171, 23-32	4.7	75	
24	PEpura. FMC Formacion Medica Continuada En Atencion Primaria, 2001 , 8, 215-229	O		
23	Estrategias terapūticas en el prurigo nodular. <i>Piel</i> , 2001 , 16, 360-364	0.1	5	
22	An immunohistopathologic study in cutaneous necrotizing vasculitis. <i>Journal of Cutaneous Pathology</i> , 2000 , 27, 130-5	1.7	15	
21	Vanadate fully stimulates insulin receptor substrate-1 associated phosphatidyl inositol 3-kinase activity in adipocytes from young and old rats. <i>FEBS Letters</i> , 1998 , 425, 298-304	3.8	31	
20	Changes in the kinase activity of the insulin receptor account for an increased insulin sensitivity of mammary gland in late pregnancy. <i>Endocrinology</i> , 1998 , 139, 520-6	4.8	19	
19	Papular acrodermatitis of childhood related to poxvirus and parvovirus B19 infection. <i>Cutis</i> , 1998 , 61, 265-7	0.4	24	

18	Sequential combined therapy with thalidomide and narrow-band (TL01) UVB in the treatment of prurigo nodularis. <i>Dermatology</i> , 1997 , 195, 359-61	4.4	53
17	Dideoxyinosine-associated Ofuji papuloerythroderma in an HIV-infected patient. <i>Dermatology</i> , 1997 , 195, 410-1	4.4	20
16	In vivo insulin-dependent glucose uptake of specific tissues is decreased during aging of mature Wistar rats. <i>Endocrinology</i> , 1997 , 138, 49-54	4.8	62
15	P-37: Role of the C-terminal domain of insulin receptor Eubunit in aging: effects of truncation. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 1996 , 104, 101-102	2.3	4
14	Cutis Marmorata Telangiectatica Congenita or Neonatal Lupus?. Pediatrics International, 1996, 13, 230	-232	
13	Impairment of the liver insulin receptor autoactivation cascade at full-term pregnancy in the rat. <i>Biochemical Journal</i> , 1995 , 311 (Pt 2), 523-9	3.8	2
12	Papular-purpuric gloves-and-socks syndrome related to cytomegalovirus infection. <i>Dermatology</i> , 1995 , 191, 269-70	4.4	47
11	Bacillary angiomatosis presenting as a malleolar ulcer. <i>Archives of Dermatology</i> , 1995 , 131, 963-964		6
10	Regulation of cyclic AMP synthesis and degradation is modified in rat liver at late gestation. <i>Biochemical Journal</i> , 1992 , 286 (Pt 2), 419-24	3.8	2
9	Effect of aging on the kinetic characteristics of the insulin receptor autophosphorylation in rat adipocytes. <i>Archives of Biochemistry and Biophysics</i> , 1992 , 296, 231-8	4.1	20
8	Activation of phosphatidylinositol-3-kinase by insulin is mediated by both A and B human insulin receptor types. <i>Biochemical and Biophysical Research Communications</i> , 1991 , 174, 123-7	3.4	15
7	The two isotypes of the human insulin receptor (HIR-A and HIR-B) follow different internalization kinetics. <i>Biochemical and Biophysical Research Communications</i> , 1991 , 177, 1013-8	3.4	90
6	Short-term effect of glutamine on the incorporation of glucose-carbon into nucleic acids in Ehrlich ascites tumour cells. <i>Biochimie</i> , 1990 , 72, 291-3	4.6	1
5	Insulin receptor kinase activity in rat adipocytes is decreased during aging. <i>Biochemical and Biophysical Research Communications</i> , 1989 , 160, 303-9	3.4	28
4	Tyrosine kinase activity of liver insulin receptor is inhibited in rats at term gestation. <i>Biochemical Journal</i> , 1989 , 263, 267-72	3.8	15
3	An Mr 180,000 protein is an endogenous substrate for the insulin-receptor-associated tyrosine kinase in human placenta. <i>Biochemical Journal</i> , 1987 , 243, 797-801	3.8	27
2	Evidence that (a) serine specific protein kinase(s) different from protein kinase C is responsible for the insulin-stimulated actin phosphorylation by placental membrane. <i>FEBS Letters</i> , 1986 , 201, 81-6	3.8	9
1	Nitrogen movement between host and tumor in mice inoculated with Ehrlich ascitic tumor cells. <i>Cancer Research</i> , 1984 , 44, 3831-5	10.1	72